COMING SOON – Efficacy and Safety of LY3209590 compared with Insulin Degludec in Participants with Type 1 Diabetes Treated with Multiple Daily Injection Therapy
A Phase 3, Multicenter, Randomized, Parallel-Design, Open Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared with Insulin Degludec in Participants with Type 1 Diabetes Treated with Multiple Daily Injection Therapy (QWINT-5)